Major Korean pharmaceutical and biotech companies are set to participate in BIO USA 2026, held in San Diego, USA, starting June 22. Key players such as Samsung Biologics, Celltrion, SK Biopharm, Lotte Biologics, Dong-A Socio Group, Oscotec, and Onconic Therapeutics will be present, with primary objectives including technology exports, CDMO contract wins, and the expansion of global partnerships. According to Yonhap News, each company plans to showcase its R&D capabilities, production capacity, and AI-based drug development strategies to attract global partners. This event is not merely an exhibition but a practical business arena that could influence K-Bio investment sentiment and corporate valuations in the second half of the year. The strategies presented by Korean companies at this BIO USA are quite clear. Samsung Biologics will highlight its CDMO services and expanded production capacity, Celltrion its biosimilar competitiveness in the U.S. market and AI technology, and SK Biopharm its digital health and AI-based R&D strategies. Lotte Biologics will promote its Songdo campus and ADC-related capabilities, while other companies will also emphasize their respective pipelines and platform competitiveness. In essence, Korean biotech has moved beyond mere 'participation' to a stage where it competes on what it can bring to the negotiating table. Notably, AI, ADC, organoids, and customized manufacturing capabilities directly align with the interests of global big pharma. Frankly, the market no longer moves on expectations alone. Meaningful outcomes require actual technology transfer agreements, follow-up meetings leading to major partnerships, or securing new CDMO clients. Therefore, it is accurate to view this BIO USA not as a platform for K-Bio to discuss 'potential,' but as an arena to prove its marketable competitiveness. Successful outcomes could catalyze a turnaround in sector sentiment in the second half, but conversely, if participation remains merely an event without tangible results, the selective market trend could intensify. Looking to the future, this week presents an opportunity for Korean biotech to redefine its global positioning.